Hans Sauer
Hans Sauer is Deputy General Counsel and Vice President for Intellectual Property for the Biotechnology Innovation Organization (BIO), a major trade association representing more than 1,000 biotechnology companies from the medical, agricultural, environmental, and industrial sectors. At BIO, he advises the organization’s board of directors, amicus committee, and various staff committees on patent and other intellectual-property-related matters. Before taking his current position at BIO in 2006, he was chief patent counsel for MGI Pharma Inc. in Bloomington, MN, and senior patent counsel for Guilford Pharmaceuticals Inc. in Baltimore, MD. Mr. Sauer holds a M.S. degree in biology from the University of Ulm in his native Germany, a Ph.D. in neuroscience from the University of Lund, Sweden, and a J.D. degree from Georgetown University Law Center, where he serves as adjunct professor.
Posts by Hans Sauer
Waiving IP Rights During Times of COVID: A ‘False Good Idea’
The Re-Written American Axle Opinion Does Not Bring Peace of Mind for Section 101 Stakeholders
Why Helsinn v. Teva Creates Inscrutable Uncertainty About the Scope of Prior Art Instead of Confirming Longstanding Law
Price Controls and Compulsory Licensing Reduce Patient’s Healthcare Options
Expansion of the Blocking Patent Doctrine: Trading Logic for Gremlins
Conjecture and Speculation in Patent Obviousness: Trading Logic for Hindsight
Doubling Down on Double Adjudication – the MerchSource post-issuance review model
Some Observations on Drug Patents – A Response to Arie Michelsohn
The U.S. Government’s Position in ACLU v. Myriad Genetics: Observations on a ‘Waste of Time and Space’
